Issue – OBR

July 2017:

Table of contents

Latest in Cost and Value Discussion at ASCO '17

ODAC Recommends First Potential Gene Therapy and Two Biosimilars

June 2017:

Table of contents

Highlights from 2017 ASCO: The Practice Changing, and the Promising

Patient-Reported Outcomes (PRO) Improve the Lives of People with Cancer

2017 ASCO: It’s Back to “Precision Medicine”

May 2017:

Table of contents

Cancer Care Costs Pose a Huge Financial Burden on Patients

Hypothetical OCM. 2.0 Addresses Obstacles and Opportunities

Q&A with Ben Jones, VP, Govt Relations & Public Policy, McKesson Specialty Health

Oncology Care Model: Early Learnings

April 2017:

Table of contents

State of Cancer Care: Opportunities and Challenges

AACR 2017 Roundup: Bugs, Drugs, and an Electric Hat

Market Forces, Value-Based Frameworks, and Drug Pricing

March 2017:

Table of contents

Cancer Patients Face Uncertainty with ACA’s Repeal/Replace

Using Real-World Evidence in the Cancer Care Continuum

February 2017:

Table of contents

CAR T-Cell Therapy on Fast Track for Commercialization in 2017

Can Social Media Improve Patient Participation in Cancer Clinical Trials?

January 2017:

Table of contents

Phase 3 Hits and Misses of 2016

2017 Forecast Series—Laurie Glimcher, MD, President and CEO, Dana-Farber Cancer Institute, Discusses the Cancer “Moonshot” Initiative

2017 Forecast Series—Steve Miller, MD, Senior Vice President, Chief Medical Officer, Express Scripts, Talks About Oncology Drug Spending and Value

2017 Forecast Series—Barry Russo, Chief Executive Officer, The Center for Blood and Cancer Disorders Discusses OCM and MIPS in 2017

2017 Forecast Series—Amy McKee, MD, Acting Deputy Director, CDER's Office of Hematology and Oncology Products, Comments on the FDA Oncology Center of Excellence

November 2016:

Table of contents

Is Your Practice Ready to Maximize the OCM Performance Payment?

The Evolving Influence of Integrated Delivery Networks (IDNs) in Oncology

CVS Policy Reversal Offers Temporary Relief for Dispensing Practices

October 2016:

Table of contents

Practice-Changing Potential for Breast Cancer

Biosimilars: A Brave New World but Uncertain Terrain

At ESMO: One Anti-PD1 Agent Moves to the Head of the Line in Advanced NSCLC

Op-Ed: Our View on Value Frameworks in Oncology: Proposing Principles for Value Framework Development

September 2016:

Table of contents

The Next Wave of Immunotherapies: Costimulators

EHA 2016: Stopping TKIs in CML and Improving Overall Survival in ALL

Study Finds Cancer Costs Dont Outpace Other Health Care

July 2016:

Table of contents

Memorable Moments: The ASCO 2016 Experience for Physicians

ASCO Roundup: Biosimilars, Precision Medicine, and New Inroads

Biomarkers for Immunotherapy: Research at ASCO and Treatment Implication

Monoclonal Antibodies in Multiple Myeloma Offer Survival Hope

June 2016:

Table of contents

PD-L1 Biomarker Status: To Test or Not to Test?

Value Tools at ASCO 2016: Building a Framework for Prime Time

May 2016:

Table of contents

Getting Ready for Chicago: A Behind the Scenes Look at Designing the Annual Meeting

AACR Round Up: Immunotherapy, Breast Cancer, and Beyond

What’s in Store for ASCO 2016? Kantar Health Offers a Preview

April 2016:

Table of contents

The Uphill Climb of Precision Medicine

Why Histology Matters in Lung Cancer Treatment: Updates from the Annual Winter Lung Cancer Conference

March 2016:

Table of contents

Better Care, Better Payment, and Savings: A Win-Win-Win Approach to Payment Reform

Using Patient-Reported Outcomes (PRO) to Improve the Quality of Cancer Care

February 2016:

Table of contents

At ASH: Novel Targeted Therapies for Tough-to-Treat Blood Cancers

Hope and Hype: Questions Surround Liquid Biopsies

January 2016:

Table of contents

2016 Forecast Series - Perspective on Precision Medicine with Jennifer Carter, MD, MPH, Founder and Chief Medical Officer, N-of-One

2016 Forecast Series - Assessing Value and Clinical Benefit with Lowell E. Schnipper, MD

2016 Forecast Series - On Curing Cancer with Vincent T DeVita Jr MD

2016 Forecast Series - The Future of Immuno-Oncology with Patrick Ott, MD, MPH

Phase 3 Hits and Misses of 2015

Discussing Value in Hematology: An On-Conversation with ZS Associates

December 2015:

Table of contents

Extending and Enhancing Patient Care Beyond the Office with Patient Portals

The Evolving Role of PD-L1 Testing in Immunotherapy of Metastatic Melanoma and Non-Small Cell Lung Cancer

November 2015:

Table of contents

Oncologists Become More Vocal About Rising Costs

Evidence Development and Payer Risk: Planning the Route to Market Access

IB/MAB Worksheet

October 2015:

Table of contents

Oncotype DX® Colon Cancer Assay for Stage II Colon Cancer Integrates Colorectal Surgeons into Multidisciplinary Care

ACCC-ICLIO: Navigating the Future of Immuno-Oncology and Who’s Going to Pay for It

New Tools from NCCN and ASCO Address Value

Five Hits and a Dud: A Snapshot of the 2015 European Cancer Congress

September 2015:

Table of contents

Innovations in Precision Medicine Introduced at ASCO 2015

The Ubiquity of Immunotherapy: Whats Next?

Beyond the Peak: Four Levers to Address Quickly Plateauing Oncology Drug Sales

July 2015:

Table of contents

European Hematology Association: Remains of the Day

The Impact of BRCA Testing: Research at ASCO and Treatment Implications for Ovarian, Breast, Prostate, and Pancreatic Cancers

June 2015:

Table of contents

Cancer Immunotherapy at ASCO: Bringing Down the House

Targeted Therapies for Hematologic Malignancies Attract Attention at ASCO 2015

What Are Payers Pondering about the New Wonder Drugs?

Emerging Role for Biomarkers and Implications for Care

Value As A Decision Driver In Cancer Care: Are We There Yet?

Immunotherapies Take Center Stage at ASCO 2015

May 2015:

Table of contents

What’s in Store at ASCO 2015? Kantar Health Offers a Preview

AACR 2015: Immunotherapy Marches On

April 2015:

Table of contents

Integrated Delivery Networks and Oncology Care Delivery: Changing the Tide, or Changing the Sign Outside?

PBS “Emperor” Broadcast Stokes a Discussion on Cancer Research’s Future

SUCCESS! Repeal of the Sustainable Growth Rate Formula

March 2015:

Table of contents

ASCO, Payers, and COA React to CMMI’s New Oncology Care Model

Value-Based Decision-Making at the Bedside

February 2015:

Table of contents

5th Annual Outlook on the Biopharmaceutical Promotional Landscape in Oncology: Evolving Sales Models and Promotional Effectiveness

CAR-T Cell Therapies Moving Toward Clinic

January 2015:

Table of contents

2015 Forecast Series—Otis Brawley, MD, FACP, Chief Medical Officer, American Cancer Society (ACS)

2015 Forecast Series—ASCO Priorities and Objectives with Peter Paul Yu, MD, ASCO President

2015 Forecast Series—Bruce Gould, MD, Northwest Georgia Oncology Centers, President of Community Oncology Alliance (COA)

Phase 3 Hits and Misses for 2014

November 2014:

Table of contents

Market Conditions that Impact New Oncology Product Uptake

Patient Affordability: The Most Important Non-Clinical Attribute in Choosing Between Treatment Options

Experts Tackle Gaps in Cancer Care and Best Use of Interventions

October 2014:

Table of contents

Five Strategic Considerations for Biosimilar Commercialization

Clinical Pathways Can Lead to Cost Savings, Better Care

ESMO Redux: All-Stars and Also-Rans

Key Features of the CMMI Oncology Care Model (OCM)

September 2014:

Table of contents

Evolution of Angiogenesis Biomarkers: What the Future Holds

Oncotype DX® Colon Cancer Assay Improves Recurrence Risk Stratification in Stage II Colon Cancer Patients

The Shifting Sands of the Prostate Cancer Treatment Landscape

The Catalysts are Coming! The Catalysts are Coming!

July 2014:

Table of contents

The Complexities of Immunotherapies: CARs, TILs, and TCRs

Beyond KRAS exon 2: Research at ASCO and Important Treatment Implications for Metastatic Colorectal Cancer

Novel Therapies for Leukemia Attract Attention at ASCO 2014

June 2014:

Table of contents

The Three “A’s” of Treatment Options: Approved, Accessible and Affordable - Market Access Implications of Big News from ASCO 2014

Targeted Therapies Stay in the Spotlight: Late Breaking Studies in NSCLC, Thyroid, and Ovarian Cancers

Immunotherapies at ASCO 2014: Checkpoint Inhibitors

Hits And Misses at ASCO 2014

May 2014:

Table of contents

Newfound Risk that Providers, Payers, and Patients Are Navigating with the Implementation of the Affordable Care Act

What’s in Store at ASCO 2014? Kantar Health Offers a Preview

Can Innate Immune Cells Engage in Anti-Tumor Activity?

In Anticipation of ASCO: What’s Next for Cancer Immunotherapy…? Combinations of Course!

April 2014:

Table of contents

UnitedHealthcare: Measuring Quality Outcomes in Oncology

A Revolution in Cancer Care: Cancer Immunotherapeutics in the Pipeline

Spearheading a PSA and Co-Management Agreement Between a Practice and a Hospital: Making it Work!

March 2014:

Table of contents

The Evolving Use of White Bagging in Oncology

ASCO Reports on the State of Cancer Care in America in 2014

New Clinical Trials Designed to Better Leverage Precision Medicine

February 2014:

Table of contents

Peter B Bach Discusses New Payment Reform Models Challenging Fee For Service

Antibody Drug Conjugates and Nanotechnology Driving New Advances in Personalized Cancer Therapeutics Development

January 2014:

Table of contents

2014 Forecast Series-A conversation with Nancy Davenport-Ennis

2014 Forecast Series-Looking ahead with Matthew Farber, MA

2014 Forecast Series-Insights from Neal Meropol, MD

2014 Forecast Series-ASCO priorities and objectives with Allen S. Lichter, MD

Phase 3 Hits & Misses of 2013

Three Industry Developments in Precision Medicine in 2013 Set the Stage for Broader Availability

December 2013:

Table of contents

Lessons Learned from the First FDA-Approved Breakthrough Therapies

Health Information Exchanges: Some Community Practices Are Benefitting, Many Are Not

Innovative Cancer Care and the Initiation of the COME HOME Medical Home Program

November 2013:

Table of contents

Are GPOs Helping Community Oncology Survive?

Pancreatic Cancer May No Longer Be Immune to Therapy as Pipeline Agents Make Progress

The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion

October 2013:

Table of contents

IB/MAB Worksheet

Innovation in EHR Technology Drives Quality Oncology Care and Offers Solutions to the Challenges Facing Community Oncologists

Developing a Biosimilar Defense Strategy

September 2013:

Table of contents

FDA’s New Breakthrough Therapy Designation: What does it mean for Pricing and Market Access?

Challenges with Adherence Highlight Unmet Needs in Oncology

Cost Challenges in Developing New Oncology Drugs

July 2013:

Table of contents

An OBR Survey: Ownership and Usage of Oncology Treatment and Diagnosis Data

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

June 2013:

Table of contents

Companion Diagnostics Are Driving Support in the Evolving Regulatory Landscape

CancerLinQ Proof-of-Principle Demonstrated at 2013 ASCO Annual Meeting

“Bridges Built” at the 2013 ASCO Annual Meeting

Advances in Metastatic Melanoma Bring Price Competition, Redefinition of Value, and Likely Increased Payer Utilization Management

May 2013:

Table of contents

Outlook for Patient Support Philanthropies

ASCO 2013 Is Almost Here! Kantar Health Previews the Top Abstracts

Oncology Practice Leaders Refocusing Efforts to Improve Long Term Viability

March 2013:

Table of contents

Molecular Testing: Preparing for the New Normal in Community Oncology

Community Counts: A Discussion With ION Senior Vice President Barry Fortner, PhD, Regarding a New Initiative to Help Community Oncologists

Success Factors for Building an Oncology Business (Part One)

February 2013:

Table of contents

Tackling Rising Oncology Healthcare Costs: Aetna and The West Clinic Provide Solutions

Transitioning to Value Based Oncology: Strategies to Survive and Thrive

The Evolving Dynamics of Specialty Pharmacy in Oncology

January 2013:

Table of contents

AACR President Frank McCormick PhD Reflects on Past Progress and Looks to the Future

Forecasting 2013: A Look Forward at Issues Affecting Oncology

Anatomy of a Deal: University of Virginia Health System Acquires Hematology Oncology Patient Enterprise

November 2012:

Table of contents

Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape

Pilot Phase of Michigan Oncology Medical Home Demonstration Project Launches: Patient Satisfaction Increases, Future Phases Planned

October 2012:

Table of contents

Patient-Reported Outcomes Provide New Insights into Breast Cancer Survivors

The Business Case for Integrating Palliative Care into Oncology Practice

Can Practices Successfully Dispense Oral Anti-Cancer Agents In-House?

September 2012:

Table of contents

Oncology Practices Be Prepared! Meaningful Use Stage 2 Is Here! Well Almost

The Promise of Oral Anticancer Agents: Addressing Compliance and Affordability

The Rapidly Evolving ACO World

Are Medical Homes and ACOs the Future of Cancer Care

July 2012:

Table of contents

Ensuring a Compelling Value Proposition in Oncology

ASCO President Michael P. Link, MD, Addresses the 2012 Annual Meeting

The Promising Outlook With Immunoconjugate Therapy

PD-1 Immunotherapy Makes a Splash at ASCO

Most Popular News Stories in OBR vs Most Popular in the Media

On-Conversation with Michael Tardugno, President, CEO, Celsion Corporation

Spotlight on Cost of Cancer Care: Trastuzumab

Most Cancer Patients Will Be Treated in Integrated Delivery Networks (IDN) and Cancer Institutions by 2016, Predicts New Report

May 2012:

Table of contents

The Rise of Companion Diagnostics: A Step Towards Truly Personalized Medicine

Kantar Health’s Top Picks: What’s Hot at ASCO 2012

Peter B. Bach, MD, and the Case for Interchangeability in Oncology: A New Model for an Episode-based Payment System

Achieving Accountable Cancer Care

On-Conversation with Michael N. Neuss, MD, Chief Medical Officer of the Vanderbilt-Ingram Cancer Center

Diagnostic Testing and Clinical Pathways Move into the PA Neighborhood

Spotlight on Cost of Cancer Care: Panitumumab

March 2012:

Table of contents

January 2012:

Table of contents

September 2015 Edition Vol.11, Issue 9

Featured Articles

Archived OBR Journal Articles

2017+

July 2017:

June 2017:

May 2017:

April 2017:

March 2017:

February 2017:

January 2017:

2016+

November 2016:

October 2016:

September 2016:

July 2016:

June 2016:

May 2016:

April 2016:

March 2016:

February 2016:

January 2016:

2015+

December 2015:

November 2015:

October 2015:

September 2015:

July 2015:

June 2015:

May 2015:

April 2015:

March 2015:

February 2015:

January 2015:

2014+

November 2014:

October 2014:

September 2014:

July 2014:

June 2014:

May 2014:

April 2014:

March 2014:

February 2014:

January 2014:

2013+

December 2013:

November 2013:

October 2013:

September 2013:

July 2013:

June 2013:

May 2013:

March 2013:

February 2013:

January 2013:

2012+

November 2012:

October 2012:

September 2012:

July 2012:

May 2012:

March 2012:

January 2012:

OBR Green